

=> d his

FILE 'HOME' ENTERED AT 16:24:25 ON 10 JAN 2005

FILE 'HCAPLUS' ENTERED AT 16:24:32 ON 10 JAN 2005  
 L1 1 (US20020006606 OR US6811992)/PN  
     E US1998-85439/AP, PRN  
 L2 1 US1998-85439P/AP, PRN  
 L3 1 L1-2

FILE 'REGISTRY' ENTERED AT 16:26:46 ON 10 JAN 2005

FILE 'HCAPLUS' ENTERED AT 16:26:49 ON 10 JAN 2005  
 L4 TRA L3 1- RN : 10 TERMS

FILE 'REGISTRY' ENTERED AT 16:26:49 ON 10 JAN 2005  
 L5 10 SEA L4

FILE 'WPDX' ENTERED AT 16:26:53 ON 10 JAN 2005  
 L6 2 (US20020006606 OR US6811992)/PN  
 L7 2 US1998-85439P/AP, PRN  
 L8 2 L6-7

=> b hcap

FILE 'HCAPLUS' ENTERED AT 16:28:00 ON 10 JAN 2005  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 Jan 2005 VOL 142 ISS 3  
 FILE LAST UPDATED: 9 Jan 2005 (20050109/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all 13 tot

L3 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1999.737080 HCAPLUS  
 DN 131:346549  
 ED Entered STN: 19 Nov 1999  
 TI Method to identify JNK- and MLK-kinase inhibiting compounds for prevention of neuron death  
 IN Liu, Ya Fang  
 PA USA  
 SO PCT Int. Appl., 62 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 IC ICM G01N033-68  
 ICS G01N033-50; C12Q001-48  
 CC 1-11 (Pharmacology)  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9958982	A1	19991118	WO 1999-US10416	19990512 <--
	W: CA, JP, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 6811992	B1	20041102	US 1998-156367	19980917 <--
	CA 2331680	AA	19991112	CA 1999-2331680	19990512 <--
	EP 1078268	A1	20010228	EP 1999-922972	19990512 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

JP 2002514767	T2	20020521	JP 2000-548734	19990512 <--
US 2002006606	A1	20020117	US 2001-886964	20010621 <--
US 2002058245	A1	20020516	US 2002-42614	20020109 <--
US 2003148395	A1	20030807	US 2003-360463	20030205 <--
PRAY 1998-85439P		19980514		<--
US 1998-156367	A1	19980917		
WO 1999-US10416	W	19990512		

## CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
------------	-------	------------------------------------

WO 9958982	ICM	G01N033-68
	ICS	G01N033-50; C12Q001-48
WO 9958982	ECLA	G01N033/50D2; G01N033/68V2
US 6811992	ECLA	G01N033/50D2; G01N033/68V2
US 2002006606	ECLA	G01N033/50D2; G01N033/68V2
US 2002058245	ECLA	G01N033/50D2; G01N033/68V2
US 2003148395	ECLA	G01N033/50D2; G01N033/68V2

AB Methods are described for identifying compds. that inhibit JNK and MLK kinase activity as drugs for treating a mammal susceptible to or having a neurol. condition. Methods are also disclosed for preventing neuronal cell death and treating neurol. conditions that involve neuronal cell death, particularly neurodegenerative diseases characterized by glutamine- or kainate-mediated toxicity, e.g. Huntington's disease and Alzheimer's disease.

ST JNK MLK kinase inhibitor screening neuroprotectant; Alzheimer drug JNK MLK kinase inhibitor screening; Huntington drug JNK MLK kinase inhibitor screening; neurodegenerative disease JNK MLK kinase inhibitor screening

IT Animal cell line  
(HN33; JNK- and MLK-kinase inhibiting compound identification for prevention of neuron death)

IT Nervous system  
(Huntington's chorea; JNK- and MLK-kinase inhibiting compound identification for prevention of neuron death)

IT Anti-Alzheimer's agents  
Apoptosis  
Drug screening  
Nervous system agents  
Signal transduction, biological  
(JNK- and MLK-kinase inhibiting compound identification for prevention of neuron death)

IT Transcription factors  
RL: BPP (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)  
(c-jun; JNK- and MLK-kinase inhibiting compound identification for prevention of neuron death)

IT Amyloid precursor proteins  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)  
(carboxyl-terminal fragment; JNK- and MLK-kinase inhibiting compound identification for prevention of neuron death)

IT Nerve, disease  
(death; JNK- and MLK-kinase inhibiting compound identification for prevention of neuron death)

IT Nervous system  
(degeneration; JNK- and MLK-kinase inhibiting compound identification for prevention of neuron death)

IT Toxins  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)  
(excitotoxins; JNK- and MLK-kinase inhibiting compound identification for prevention of neuron death)

IT Mutation  
(mutated protein; JNK- and MLK-kinase inhibiting compound identification for prevention of neuron death)

IT Proteins, general, biological studies  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)  
(mutated; JNK- and MLK-kinase inhibiting compound identification for prevention of neuron death)

IT Disease models  
(neurodegeneration; JNK- and MLK-kinase inhibiting compound identification for prevention of neuron death)

IT Cell death  
(neuron; JNK- and MLK-kinase inhibiting compound identification for prevention of neuron death)

IT Cytoprotective agents

(neuroprotectants; JNK- and MLK-kinase inhibiting compound identification for prevention of neuron death)

IT Toxins  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)  
(neurotoxins; JNK- and MLK-kinase inhibiting compound identification for prevention of neuron death)

IT Proteins, specific or class  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)  
(polyglutamine stretch-expanded huntingtin; JNK- and MLK-kinase inhibiting compound identification for prevention of neuron death)

IT Phosphorylation, biological  
(protein; JNK- and MLK-kinase inhibiting compound identification for prevention of neuron death)

IT 56-86-0, L-Glutamic acid, biological studies 89-00-9, Quinolinic acid 487-79-6, Kainic acid  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)  
(JNK- and MLK-kinase inhibiting compound identification for prevention of neuron death)

IT 153190-46-6, MLK3 kinase 155215-87-5, JNK3 kinase 191808-07-8, MLK2 kinase 192230-91-4, SEK1 kinase 250649-03-7, Protein kinase MLK1  
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)  
(JNK- and MLK-kinase inhibiting compound identification for prevention of neuron death)

IT 26700-71-0, Polyglutamine 69864-43-3, Polyglutamine  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(polyglutamine stretch-expanded huntingtin; JNK- and MLK-kinase inhibiting compound identification for prevention of neuron death)

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Dickens, M; Science 1997, V277, P693 HCAPLUS  
(2) University of Massachusetts; WO 9918193 A 1999 HCAPLUS

=> b reg  
FILE "REGISTRY" ENTERED AT 16:28:08 ON 10 JAN 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 7 JAN 2005 HIGHEST RN 810025-80-0  
DICTIONARY FILE UPDATES: 7 JAN 2005 HIGHEST RN 810025-80-0

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> d 1de 15 tot

L5 ANSWER 1 OF 10 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 250649-03-7 REGISTRY  
CN Kinase (phosphorylating), protein, MLK1 (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN Mixed lineage kinase 1  
CN Multiple lineage kinase 1  
CN Protein kinase MLK1  
MF Unspecified  
CI MAN  
SR CA  
LC STN Files: BIOSIS, CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL  
DT.CA CAPplus document type: Journal; Patent  
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PROC

(Process); USES (Uses)  
 RL.NP Roles from non-patents: BIOL (Biological study); OCCU (Occurrence);  
 PROC (Process)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
 16 REFERENCES IN FILE CA (1907 TO DATE)  
 16 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 2 OF 10 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 192230-91-4 REGISTRY  
 CN Kinase (phosphorylating), gene c-jun protein N-terminal kinase/p38 kinase (9CI) (CA INDEX NAME)

## OTHER NAMES:

CN Gene c-jun protein N-terminal kinase kinase 1  
 CN Gene jkk-1 protein kinase  
 CN JNK/p38 kinase kinase  
 CN JNKK1  
 CN JNKK1 kinase  
 CN JNKK1 protein kinase  
 CN Jun N-terminal kinase kinase 1  
 CN MAP kinase kinase 4  
 CN MAP2K4  
 CN MEK4 kinase  
 CN Mitogen-activated protein kinase hep  
 CN Mitogen-activated protein kinase kinase 4  
 CN MKK4 kinase  
 CN p38 SAPK  
 CN Protein kinase MEK4  
 CN Protein kinase MKK4  
 CN Protein kinase MPK4  
 CN SAPK/ERK kinase-1  
 CN SEK1 protein kinase  
 CN SKK1 protein kinase  
 CN Stress-activated protein kinase kinase-1

DR 150316-15-7, 179466-44-5, 291756-33-7

MF Unspecified

CI MAN

SR CA

LC STN Files: BIOSIS, CA, CAPLUS, TOXCENTER, USPATFULL

DT.CA CAplus document type: Conference; Dissertation; Journal; Patent

RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study);  
 OCCU (Occurrence); PROC (Process); PRP (Properties); USES (Uses)

RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study)

RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study);  
 FORM (Formation, nonpreparative); OCCU (Occurrence); PREP  
 (Preparation); PROC (Process); PRP (Properties); USES (Uses)

RLD.NP Roles for non-specific derivatives from non-patents: BIOL (Biological study)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

458 REFERENCES IN FILE CA (1907 TO DATE)  
 7 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 458 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 3 OF 10 REGISTRY COPYRIGHT 2005 ACS on STN

RN 191808-07-8 REGISTRY  
 CN Kinase (phosphorylating), protein, MLK2 (9CI) (CA INDEX NAME)

## OTHER NAMES:

CN Mixed lineage kinase 2  
 CN Mixed-lineage protein kinase 2  
 CN MLK2 kinase  
 CN MST/MLK2 kinase  
 CN Multiple lineage kinase 2  
 CN Protein kinase MLK2  
 MF Unspecified

CI MAN

SR CA

LC STN Files: BIOSIS, CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

DT.CA CAplus document type: Dissertation; Journal; Patent

RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study);  
 PREP (Preparation); PROC (Process); USES (Uses)

RL.NP Roles from non-patents: BIOL (Biological study); OCCU (Occurrence);  
 PROC (Process); PRP (Properties); USES (Uses)

RLD.NP Roles for non-specific derivatives from non-patents: BIOL (Biological study);  
 PREP (Preparation); PROC (Process)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
 37 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 37 REFERENCES IN FILE CAPLUS (1907 TO DATE)

LS ANSWER 4 OF 10 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 155215-87-5 REGISTRY  
 CN Kinase (phosphorylating), gene c-jun protein N-terminal (9CI) (CA INDEX NAME)  
 OTHER NAMES:  
 CN c-Jun amino-terminal kinase  
 CN c-Jun amino-terminal protein kinase  
 CN c-Jun kinase  
 CN c-Jun N-terminal kinase  
 CN c-Jun N-terminal protein kinase  
 CN Gene c-jun protein kinase  
 CN JNK  
 CN JNK kinase  
 CN JNK protein kinase  
 CN Jun kinase  
 CN JUN N-terminal kinase  
 CN Jun NH2-terminal kinase  
 CN Jun-NH2 kinase  
 CN Protein kinase JNK  
 CN Protein kinase sapk1  
 CN Protein kinase SAPK1.gamma.  
 CN SAP kinase  
 CN SAPK.gamma. kinase  
 CN SAPK/JNK kinase  
 CN Stress-activated protein kinase  
 CN Stress-activated protein kinase-.gamma.  
 DR 177893-53-7, 143180-76-1  
 MF Unspecified  
 CI MAN  
 SR CA  
 LC STN Files: ADISNEWS, AGRICOLA, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAPLUS, CHEMCATS, CIN, EMBASE, PROMT, TOXCENTER, USPAT2, USPATFULL  
 DT.CA Caplus document type: Conference; Dissertation; Journal; Patent; Report  
 RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); MSC (Miscellaneous); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); USES (Uses)  
 RLD.P Roles for non-specific derivatives from patents: ANST (Analytical study); BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)  
 RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)  
 RLD.NP Roles for non-specific derivatives from non-patents: ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); USES (Uses)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
 5330 REFERENCES IN FILE CA (1907 TO DATE)  
 60 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 5346 REFERENCES IN FILE CAPLUS (1907 TO DATE)

LS ANSWER 5 OF 10 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 153190-46-6 REGISTRY  
 CN Kinase (phosphorylating), gene PTK1 protein (9CI) (CA INDEX NAME)  
 OTHER NAMES:  
 CN Gene PTK1 protein kinase  
 CN Gene PTK1 tyrosine kinase  
 CN Mixed lineage kinase 3  
 CN Mixed lineage kinase MLK3  
 CN MLK3 kinase  
 CN Multiple lineage kinase 3  
 CN Protein kinase MLK3  
 CN Protein tyrosine kinase 1  
 MF Unspecified  
 CI MAN  
 SR CA  
 LC STN Files: BIOSIS, CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL  
 DT.CA Caplus document type: Dissertation; Journal; Patent

RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study); MSC (Miscellaneous); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); USES (Uses)  
 RL.NP Roles from non-patents: BIOL (Biological study); OCCU (Occurrence); PROC (Process); PRP (Properties)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
 78 REFERENCES IN FILE CA (1907 TO DATE)  
 78 REFERENCES IN FILE CAPLUS (1907 TO DATE)

LS ANSWER 6 OF 10 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 69864-43-3 REGISTRY  
 CN Poly[imino[(1S)-1-(3-amino-3-oxopropyl)-2-oxo-1,2-ethanediyl]] (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Poly[imino[1-(3-amino-3-oxopropyl)-2-oxo-1,2-ethanediyl]], (S)-  
 OTHER NAMES:

CN Poly(glutamine), SRU  
 CN Poly(L-glutamine), SRU  
 CN Poly-L-glutamine  
 CN Polyglutamine  
 DR 26603-78-1  
 MF (C5 H8 N2 O2)n  
 CI PMS, COM  
 PCT Polyamide

LC STN Files: ADISNEWS, AGRICOLA, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAPLUS, CEN, CIN, EMBASE, PIRA, PROMT, TOXCENTER, USPAT2, USPATFULL

DT.CA Caplus document type: Conference; Dissertation; Journal; Patent; Preprint


RL.P Roles from patents: BIOL (Biological study); MSC (Miscellaneous); PREP (Preparation); PROC (Process); PRP (Properties); USES (Uses)

RLD.P Roles for non-specific derivatives from patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); USES (Uses)

RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); MSC (Miscellaneous); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)

RLD.NP Roles for non-specific derivatives from non-patents: BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent)

\*\*RELATED POLYMERS AVAILABLE WITH POLYLINK\*\*



305 REFERENCES IN FILE CA (1907 TO DATE)  
 25 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 307 REFERENCES IN FILE CAPLUS (1907 TO DATE)

LS ANSWER 7 OF 10 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 26700-71-0 REGISTRY  
 CN L-Glutamine, homopolymer (9CI) (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN Glutamine, L-, peptides (8CI)  
 OTHER NAMES:  
 CN Glutamine homopolymer  
 CN Poly-L-glutamine  
 CN Polyglutamine  
 FS STEREOSEARCH  
 MF (C5 H10 N2 O3)x  
 CI PMS, COM  
 PCT Polyamide, Polyamide formed  
 LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CEN, CIN, DIOGENES, EMBASE, MEDLINE, PIRA, PROMT, TOXCENTER, USPAT2, USPATFULL  
 DT.CA Caplus document type: Conference; Dissertation; Journal; Patent;

**Preprint**

RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study); MSC (Miscellaneous); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)

RLD.P Roles for non-specific derivatives from patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); PREP (Preparation); PROC (Process); USES (Uses)

RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); MSC (Miscellaneous); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)


RLD.NP Roles for non-specific derivatives from non-patents: BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)

**\*\*RELATED POLYMERS AVAILABLE WITH POLYLINK\*\***

CM 1

CRN 56-85-9  
CMF C5 H10 N2 O3

Absolute stereochemistry.



749 REFERENCES IN FILE CA (1907 TO DATE)  
 42 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 751 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L5 ANSWER 8 OF 10 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 487-79-6 REGISTRY  
 CN 3-Pyrrolidineacetic acid, 2-carboxy-4-(1-methylethethyl)-, (2S,3S,4S)- (9CI) (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN 3-Pyrrolidineacetic acid, 2-carboxy-4-(1-methylethethyl)-, [2S-(2.alpha.,3.beta.,4.beta.)]-  
 CN 3-Pyrrolidineacetic acid, 2-carboxy-4-isopropenyl- (6CI, 7CI, 8CI)  
 OTHER NAMES:  
 CN (-)-.alpha.-Kainic acid  
 CN (-)-Kainic acid  
 CN (2S,3S,4S)-2-Carboxy-4-isopropenylpyrrolidine-3-acetic acid  
 CN .alpha.-Kainic acid  
 CN Digenic acid  
 CN Digenin  
 CN Helminal  
 CN Kainic acid  
 CN L-.alpha.-Kainic acid  
 FS STEREOSEARCH  
 DR 4071-38-9, 46398-96-3  
 MF C10 H15 N 04  
 CI COM  
 LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN\*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DDFU, DRUGU, EMBASE, HODOC\*, IPA, MEDLINE, MRCK\*, MSDS-OHS, NAPRALERT, NIOSHTIC, PROMT, RTECS\*, SPECINFO, TOXCENTER, USAN, USPAT2, USPATFULL, VETU  
 (\*File contains numerically searchable property data)

Other Sources: WHO

DT.CA Cplus document type: Book; Conference; Dissertation; Journal; Patent; Report  
 RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study); MSC (Miscellaneous); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)  
 RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); USES (Uses)  
 RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); MSC (Miscellaneous); OCCU

(Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)  
 RLD.NP Roles for non-specific derivatives from non-patents: ANST (Analytical study); BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)


Absolute stereochemistry. Rotation (-).



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

4629 REFERENCES IN FILE CA (1907 TO DATE)  
 45 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 4632 REFERENCES IN FILE CAPLUS (1907 TO DATE)  
 26 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L5 ANSWER 9 OF 10 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 89-00-9 REGISTRY  
 CN 2,3-Pyridinedicarboxylic acid (8CI, 9CI) (CA INDEX NAME)  
 OTHER NAMES:  
 CN NSC 13127  
 CN NSC 18836  
 CN NSC 403247  
 CN Quinolinic acid  
 FS 3D CONCORD  
 MF C7 H5 N O4  
 CI COM  
 LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN\*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DDFU, DRUGU, EMBASE, GMELIN\*, HODOC\*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK\*, NIOSHTIC, PROMT, PS, RTECS\*, SPECINFO, SYNTHLINE, TOXCENTER, UOLIDAT, USPAT2, USPATFULL  
 (\*File contains numerically searchable property data)  
 Other Sources: EINECS\*\*, NDSL\*\*, TSCA\*\*  
 (\*\*Enter CHEMLIST File for up-to-date regulatory information)  
 DT.CA CPlus document type: Book; Conference; Dissertation; Journal; Patent; Report  
 RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)  
 RLD.P Roles for non-specific derivatives from patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)  
 RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); MSC (Miscellaneous); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role in record)  
 RLD.NP Roles for non-specific derivatives from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1859 REFERENCES IN FILE CA (1907 TO DATE)

94 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 1862 REFERENCES IN FILE CAPIUS (1907 TO DATE)  
 20 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

LS ANSWER 10 OF 10 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 56-86-0 REGISTRY  
 CN L-Glutamic acid (9CI) (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN Glutamic acid, L- (7CI, 8CI)  
 OTHER NAMES:  
 CN (2S)-2-Aminopentanedioic acid  
 CN (S)-(+)-Glutamic acid  
 CN (S)-2-Aminopentanedioic acid  
 CN (S)-Glutamic acid  
 CN .alpha.-Aminoglutaric acid  
 CN .alpha.-Glutamic acid  
 CN 1-Aminopropane-1,3-dicarboxylic acid  
 CN 2-Aminoglutaric acid  
 CN 2-Aminopentanedioic acid  
 CN Aciglut  
 CN E 620  
 CN Glusate  
 CN Glutacid  
 CN Glutamic acid  
 CN Glutamicol  
 CN Glutamidex  
 CN Glutaminic acid  
 CN Glutaminol  
 CN Glutaton  
 CN L-(+)-Glutamic acid  
 CN L-.alpha.-Aminoglutaric acid  
 CN L-Glutaminic acid  
 CN L-Glutaminic acid  
 CN NSC 143503  
 CN Pentanedioic acid, 2-amino-, (S)-  
 FS STEREOSEARCH  
 DR 6899-05-4, 10549-13-0, 138-16-9  
 MF C5 H9 N O4  
 CI COM  
 LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN\*, BIOBUSINESS,  
 BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAPIUS, CASREACT, CBNB, CEN,  
 CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM\*,  
 DIOGENES, DIPPR\*, DRUGU, EMBASE, ENCOMPLIT, ENCOMPLIT2, ENCOMPPAT,  
 ENCOMPPAT2, GMELIN\*, HODOC\*, HSDB\*, IFICDB, IFIPAT, IFIUDB, IPA,  
 MEDLINE, MRCK\*, MSDS-OHS, NAPRALERT, NIOSHTIC, PDLCOM\*, PIRA, PROMT, PS,  
 RTECS\*, SPECINFO, SYNTHLINE, TOXCENTER, TULSA, ULIDAT, USAN, USPAT2,  
 USPATFULL, VETU, VTB  
 (\*File contains numerically searchable property data)  
 Other Sources: DSL\*\*, EINECS\*\*, TSCA\*\*, WHO  
 (\*\*Enter CHEMLIST File for up-to-date regulatory information)  
 DT.CA CAPIUS document type: Book; Conference; Dissertation; Journal; Patent;  
 Preprint; Report  
 RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study);  
 CMBI (Combinatorial study); FORM (Formation, nonpreparative); MSC  
 (Miscellaneous); OCCU (Occurrence); PREP (Preparation); PROC (Process);  
 PRP (Properties); RACT (Reactant or reagent); USES (Uses); NORL (No role  
 in record)  
 RLD.P Roles for non-specific derivatives from patents: ANST (Analytical  
 study); BIOL (Biological study); FORM (Formation, nonpreparative); MSC  
 (Miscellaneous); OCCU (Occurrence); PREP (Preparation); PROC (Process);  
 PRP (Properties); RACT (Reactant or reagent); USES (Uses)  
 RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological  
 study); CMBI (Combinatorial study); FORM (Formation, nonpreparative);  
 MSC (Miscellaneous); OCCU (Occurrence); PREP (Preparation); PROC  
 (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses);  
 NORL (No role in record)  
 RLD.NP Roles for non-specific derivatives from non-patents: ANST (Analytical  
 study); BIOL (Biological study); FORM (Formation, nonpreparative); OCCU  
 (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT  
 (Reactant or reagent); USES (Uses)

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

61152 REFERENCES IN FILE CA (1907 TO DATE)  
 2019 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 61210 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> b wpix

FILE 'WPIX' ENTERED AT 16:28:16 ON 10 JAN 2005  
 COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE LAST UPDATED: 7 JAN 2005 <20050107/UP>  
 MOST RECENT DERWENT UPDATE: 200502 <200502/DW>  
 DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,  
 PLEASE VISIT:  
[<<<](http://www.stn-international.de/training_center/patents/stn_guide.pdf)

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE  
<http://thomsonderwent.com/coverage/latestupdates/> <<<

>>> FOR INFORMATION ON ALL DERWENT WORLD PATENTS INDEX USER  
 GUIDES, PLEASE VISIT:  
<http://thomsonderwent.com/support/userguides/> <<<

>>> NEW! FAST-ALERTING ACCESS TO NEWLY-PUBLISHED PATENT  
 DOCUMENTATION NOW AVAILABLE IN DERWENT WORLD PATENTS INDEX  
 FIRST VIEW - FILE WPIFV.  
 FOR FURTHER DETAILS: [<<<](http://www.thomsonderwent.com/dwpifv)

>>> NEW DISPLAY FORMAT HITSTR ADDED ALLOWING DISPLAY OF  
 HIT STRUCTURES WITHIN THE BIBLIOGRAPHIC DOCUMENT <<<

>>> SMILES and ISOSMILES strings are no longer available as  
 Derwent Chemistry Resource display fields <<<

>>> THE CPI AND EPI MANUAL CODES HAVE BEEN REVISED FROM UPDATE 200501.  
 PLEASE CHECK:  
<http://thomsonderwent.com/support/dwpiref/reftools/classification/code-revision/>  
 FOR DETAILS. <<<

=> d all 18 tot

L8 ANSWER 1 OF 2 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN  
 AN 2002-187722 [24] WPIX  
 CR 2000-086442 [07]  
 DNC C2002-057884  
 TI Method of screening a compounds ability to prevent neuronal cell death in  
 mammals, affected with neurological conditions such as Huntington's  
 disease, Alzheimer's disease.  
 DC B03 B04 D16 S03  
 IN LIU, Y F  
 PA (LIUY-I) LIU Y F  
 CYC 1  
 PI US 2002006606 A1 20020117 (200224)\* 29 C12Q001-00 <--  
 ADT US 2002006606 A1 ~~Provisional US 1998-85439P 19980514, Div ex US~~  
 1998-156367 19980917, US 2001-886964 20010621  
 PRAI ~~US 1998-85439P 19980514, US 1998-156367~~  
 19980917; US 2001-886964 20010621  
 IC ICM C12Q001-00  
 AB US2002006606 A UPAB: 20020610  
 NOVELTY - A compound found to have Mixed-lineage kinase (MLK) and/or  
 c-Jun N-terminal kinase (JNK) inhibitor activity, is treated with  
 mammalian neurons having activated MLK and/or JNK activity. A decrease in  
 the number of dead neurons (in the presence of compound), in comparison  
 to number of dead neurons (in the compound's absence), indicates the

anti-neuronal apoptosis effect of the compound.

**DETAILED DESCRIPTION** - A compound is treated with MLK and/or JNK protein and a substrate. The level of JNK and/or MLK activity is measured, if the activity of the JNK and/or MLK is found to decrease in the presence of the compound (when compared to the activity in the absence of the compound), the compound is confirmed to be a JNK and/or MLK inhibitor. This compound is treated with mammalian neurons having activated Mixed-lineage kinase (MLK) and/or c-Jun N-terminal kinase (JNK) activity. The number of dead neurons is determined. A decrease in the number of dead neurons (in the presence of compound), in comparison to the normal number of dead neurons, indicates the ability of the compound to prevent neuronal death.

**USE** - For treating mammals with neurological diseases such as Huntington's disease or Alzheimer's disease, which involves nerve cell death by glutamate or kainic acid mediated excitotoxicity (claimed).

Dwg. 0/14

FS CPI EPI  
 FA AB; DCN  
 MC CPI: B04-F0200E; B04-L04; B11-C08; B11-C08E1; B11-C10; B12-K04A;  
 B12-K04A5; B14-D03; B14-H04; B14-J01; B14-J01A3; B14-J01A4;  
 B14-J01B3; B14-J01B4; B14-J05; B14-J07; B14-N16; B14-N17B; B14-S01;  
 D05-A02B; D05-H09; D05-H14B2

L8 ANSWER 2 OF 2 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN  
 AN 2000-086442 [07] WPIX  
 CR 2002-187722 [21]  
 DNN N2000-067845 DNC C2000-024051  
 TI Method of screening a compounds ability to prevent neuronal cell death in mammals, affected with neurological conditions such as Huntington's disease, Alzheimer's disease.  
 DC B03 B04 D16 S03  
 IN LIU, Y F  
 PA (LIUY-I) LIU Y F  
 CYC 22  
 PI WO 9958982 A1 19991118 (200007)\* EN 62 G01N033-68  
 RW: AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE  
 W: CA JP US  
 EP 1078268 A1 20010228 (200113) EN G01N033-68  
 R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE  
 US 2002006606 A1 20020117 (200224) 29 C12Q001-00 <--  
 JP 2002514767 W 20020521 (200236) 71 G01N033-50  
 US 2002058245 A1 20020516 (200237) C12Q001-00  
 US 2003148395 A1 20030807 (200358) G01N033-53  
 US 6811992 B1 20041102 (200472) C12Q001-00 <--  
 ADT WO 9958982 A1 WO 1999-US10416 19990512; EP 1078268 A1 EP 1999-922972  
 19990512, WO 1999-US10416 19990512; US 2002006606 A1 ~~Provisional US 1998-854399P 19980514~~, Div ex US 1998-156367 19980917, US 2001-886964  
 20010621; JP 2002514767 W WO 1999-US10416 19990512, JP 2000-548734  
 19990512; US 2002058245 A1 ~~Provisional US 1998-854399P 19980514~~,  
 Cont of US 1998-156367 19980917, US 2002-42614 20020109; US 2003148395 A1  
~~Provisional US 1998-854399P 19980514~~, Cont of US 1998-156367  
 19980917, US 2003-360463 20030205; US 6811992 B1 ~~Provisional US 1998-854399P 19980514~~, US 1998-156367 19980917  
 FDT EP 1078268 A1 Based on WO 9958982; JP 2002514767 W Based on WO 9958982  
 PRAI US 1998-156367 19980917; ~~US 1998-854399P 19980514~~, US 2001-886964 20010621; US 2002-42614  
~~19980514~~, US 2003-360463 20030205  
 IC ICM C12Q001-00; G01N033-50; G01N033-53; G01N033-68  
 ICS C12P021-06; C12Q001-48; C12Q001-68; G01N033-15; G01N033-567  
 AB WO 9958982 A UPAB: 20020618  
 NOVELTY - A compound found to have Mixed-lineage kinase (MLK) and/or c-Jun N-terminal kinase (JNK) inhibitor activity, is treated with mammalian neurons having activated MLK and/or JNK activity. A decrease in the number of dead neurons (in the presence of compound), in comparison to number of dead neurons (in the compounds absence), indicates the anti-neuronal apoptosis effect of the compound.

**DETAILED DESCRIPTION** - A compound is treated with MLK and/or JNK protein and a substrate. The level of JNK and/or MLK activity is measured, if the activity of the JNK and/or MLK is found to decrease in the presence of the compound (when compared to the activity in the absence of the compound), the compound is confirmed to be a JNK and/or MLK inhibitor. This compound is treated with mammalian neurons having activated Mixed-lineage kinase (MLK) and/or c-Jun N-terminal kinase (JNK) activity. The number of dead neurons is determined. A decrease in the number of dead neurons (in the presence of compound), in comparison to the normal number of dead neurons, indicates the ability of the compound

to prevent neuronal death.

USE - For treating mammals with neurological diseases such as Huntington's disease or Alzheimer's disease, which involves nerve cell death by glutamate or kainic acid mediated excitotoxicity (claimed).

Dwg. 0/14

FS CPI EPI  
FA AB; DCN  
MC CPI: B04-F02; B04-N02; B11-C08E2; B12-K04A; D05-H09  
EPI: S03-E14H

=> b home  
FILE 'HOME' ENTERED AT 16:28:31 ON 10 JAN 2005

=>